Pfizer affirms FY25 earnings guidance, provides full-year 2026 outlook

[ad_1] Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance for fiscal 2026. The company continues to expect full-year 2025 adjusted earnings to be in the range…




